MXPA00006383A - Solid thermoformable controlled-release pharmaceutical composition - Google Patents

Abstract

The present invention relates to a new solid controlled-release pharmaceutical composition obtained by thermoforming, in the hot state, a mixture based on polymers belonging to the polymethacrylate family and medicinal active ingredient(s)

Description

PHARMACEUTICAL COMPOSITION SOLID THERMOFORMABLE CONTROLLED RELEASE DESCRIPTION OF THE INVENTION The present invention relates to a new controlled release solid pharmaceutical composition obtained by thermoforming, in the hot state, a mixture based on polymer (s) belonging to the polymethacrylate family, and active ingredient (s) medicinal Numerous pharmaceutical compositions proposed for the controlled release of pharmaceutical active ingredients have been proposed and produced, for administration by the oral, buccal, sublingual, ocular, rectal, vaginal and / or parenteral route. The objectives of these new compositions were essentially: to reduce the frequency of drug administration, - to obtain relatively constant concentrations of active ingredient in the target medium or biological site, to obtain release profiles that adapt to the pharmacological activity of the drugs. The principle most commonly used to control the release is to incorporate the active ingredient (s), together with excipients, which are more often polymeric in matrices. Whatever the matrix compositions contemplated, their production is hindered by specific manufacturing problems: a manufacturing process that is complex and consists of several stages, - stability problems of the active ingredient during the manufacturing process and in relation to the excipient used, problems in the fine control of the release rate of the active ingredient (s), which is frequently variable with time, and dependent for example on the particle size of the polymer batches with the compression processes, a manufacturing process that allows a pharmaceutical form to be obtained that is essentially adapted for only one route of administration, difficulty to achieve reproducibility of the lots due to the multiplicity of stages. The present invention is an alternative thereto which, using thermoforming techniques, allows the difficulties of a general nature described above to be overcome to obtain solid pharmaceutical compositions that allow controlled release of the active principle (s) (s) medicinal (s). In particular, it allows the number of stages in the production of final galenic forms to be reduced, limiting by this the problems of reproducibility and economic cost, as well as ensuring savings of time and space within a production chain. More especially, the invention is directed to a new application of polymethacrylates in the production of solid pharmaceutical compositions without the addition of the plasticizer and without the addition of agents that modify the release of the active ingredient (s). The invention, carried out by the Applicant, therefore allows the number of products involved in a galenic formulation to be restricted, thereby limiting storage and supply problems, as well as problems associated with environmental management . Thermoforming in the hot state is especially related to extrusion, co-extrusion, injection and co-injection techniques. These different techniques are well known in the field of plastics, and have been widely used in the automotive and packaging sectors. Due to its characteristics, and the physicochemical properties of the polymers that can be used for the thermoforming, the techniques, and especially the simple extrusion, are being applied increasingly in the field of the formulation of active ingredients. Several patents therefore describe prolonged release pharmaceutical compositions, which are obtained by extrusion of a mixture comprising at least one active ingredient, one or more polymers that can be extruded and pharmaceutically acceptable., a plasticizer and / or a retarder, the latter compound allows the release of the active ingredient to be modified. In particular, Patent Application WO96 / 14058 claims a pharmaceutical composition that especially includes as an therapeutic agent an opioid, which is dispersed in a matrix produced by extrusion. The matrix for extrusion therefore comprises an active ingredient, a hydrophobic material that can be melted, such as an alkylcellulose or an acrylic or methacrylic polymer, and a hydrophobic material, such as a fatty acid or a fatty alcohol. The latter compound serves as a retardant, and allows the release of the active ingredient to be moderate and controlled. A plasticizer is added to the mixture for the purpose of reducing the extrusion temperature. U.S. Patent No. 5,102,668 describes a pharmaceutical composition for controlled release that is pH independent, the composition is obtained by wet extrusion of polymers such as polymethacrylates, the polymers are hydrophilic at low pH and hydrophobic at high pH. The polymethacrylate preferably used is Eudragit ™ E100. The extruded materials obtained by this must subsequently undergo a spheronization step and then, advantageously, be covered with a polymer film composed of Eudragit ™ NE 30D. The association between the polymer comprising the extruded material and the polymer comprising the coating film allows the particular technical problem of this invention to be solved, i.e. the control of the release of the active ingredient as a function of the pH of the dissolution medium. . Among the prior art, patent DE 41 38 513 can also be mentioned, which presents a process for the preparation of a controlled release controlled pharmaceutical composition by continuous extrusion of a mixture comprising at least one active ingredient, a polymethacrylate, and a polymer of N-vinylpyrrolidone and / or hydroxyalkyl (methyl) cellulose. The latter compounds are used as plasticizers, and play a role in regulating the controlled release of the active ingredient. The article Pha rm. Res. 1996, 13 (5), 804-808, also describes the hot extrusion of Eudragit ™ ELOO, to which a plasticizer (at least 12% of triethyl citrate) has been added, to obtain films that allow for the controlled release of ingredients assets . Similarly, articles J. With t. I laughed 1995, 36, 243-250 and Drug De v. Ind. Pharm. 1994, 20, 1323-1339 report the use of Eudragit ™ RS PM, to which a plasticizer (triacetin) has been added to obtain granules by hot extrusion. The kinetics of release of the active ingredient is rapid, and the granules do not release all of the active ingredient. Extrusion temperatures are in the range of 130 ° C to 140 ° C. These various documents therefore describe the application of the simple extrusion technique to obtain new pharmaceutical compositions.

The techniques of injection and co-injection have been much less studied, and are mainly related to solid pharmaceutical compositions, where the matrix is based on cellulose, starch or polyethylene glycol derivatives. Finally, with respect to the coextrusion technique, Patent Application FR 2,766,088 describes a process for the production of an article, from which it is possible to manufacture controlled release devices, the process comprises carrying out the co-extrusion of the polymer and the active ingredient, the polymer used is preferably an organosilicate compound capable of crosslinking in the presence or absence of a crosslinking agent. The present invention allows, in a simple and inexpensive way, to obtain directly a controlled release solid pharmaceutical composition, by the simple mixing of one or more active ingredient (s) and polymer (s) having plastic properties and they are pharmaceutically acceptable, without the addition of plasticizers or retardants, and the mixture is thermoformed. Control of the release of the active ingredient in the composition is obtained only by judicious selection of the plastic polymer (s) used, and the amount thereof relative to that of the active ingredients) . In addition to the fact that the pharmaceutical composition according to the invention is new, it allows galenic forms to be obtained which are easily adaptable to various active ingredients and to their best mode of administration, and which ensures the controlled and reproducible release of the active ingredients. One of the objects of the invention was to achieve a controlled release solid pharmaceutical composition comprising a simple mixture of active ingredient (s), and of polymer (s) having plastic properties, the polymer (s) they are composed of the group of polymethacrylates, without addition of plasticizer and / or retardant, and without the use of solvent. Surprisingly, the solid pharmaceutical compositions of the Applicant can, due to their structure, be subjected to the technique of extrusion, co-extrusion and also injection or coinjection equally well. Employing the techniques results in matrices being obtained in shapes that have an appropriate size and geometry for various routes of administration, such as, especially, the oral, buccal, sublingual, ocular, vaginal, rectal and parenteral routes. This advantage of the pharmaceutical compositions of the present invention makes it possible to consider a manufacture, starting from the same starting material, of the galenic formulation most suitable for the active ingredient incorporated in the composition and, at the same time, for the most appropriate administration route. for the characteristics of the active ingredient and the population that has to use the formulations. Another object of the invention was to obtain a solid pharmaceutical composition wherein the matrix was adaptable to a wide range of active ingredients having very different physicochemical characteristics, for example lipophilic or hydrophilic therapeutic agents, or chemically unstable therapeutic agents. Finally, one of the objects of the invention was to obtain a solid pharmaceutical composition where possible, simply by adapting the amounts of active ingredients and used plastic polymers, to modify the release of the active ingredient by simple means. More specifically, the present invention relates to a controlled release solid pharmaceutical composition, especially administrable by the oral route, comprising a thermoformable mixture of at least one active ingredient and one or more polymers selected from the group of polymethacrylates, controlled release of the active ingredient (s) is insured only by the chemical nature and the amount of the polymethacrylate (s) 'used', and the technique employed for the manufacture of the composition. It is understood that a controlled release pharmaceutical composition is one that releases the active ingredient (s) for a period of time from several minutes (corresponding to immediate release) to a period of more than 20 hours (corresponding to to prolonged release), it being possible for the prolonged release to take place in a manner that is delayed in time after the administration of the composition. In the case of delayed release pharmaceutical compositions, the resting time (corresponding to the time between the administration of the composition and the release of the active ingredient) can be a period from 30 minutes to 8 hours, it being possible that the release of the ingredient active after this is an immediate release or a prolonged release, as defined above. Within the context of the invention, it is possible to obtain pharmaceutical compositions which show a combination of release profiles, such as an immediate release of a portion of the active ingredient (s) followed by one or more prolonged releases. It is understood that a polymethacrylate is a copolymer of methacrylic acid corresponding to a fully polymerized copolymer of methacrylic acid and acrylic or methacrylic ester. Polymethacrylates are commonly referred to by the name Eudragit ™, and may be in the form of a powder or granules. It is understood that a thermoformable mixture is a mixture capable of undergoing a transformation under the combined effect of heat and the shearing forces of a worm screw, for example extrusion, co-extrusion, injection and co-injection techniques. Among the various commercially available Eudragit ™ products, those preferably used within the context of the invention are Eudragit ™ RL and RS, which refer to ammonium methacrylate copolymers consisting of copolymerized copolymers of acrylic acid and methacrylic acid ester having a small amount of quaternary ammonium groups.

The Eudragit ™ products correspond to the general formula (I): wherein: Ri represents a hydrogen atom or a methyl group, R2 represents a methyl or ethyl group, R3 represents a methyl group, and R4 represents a group CH2-CH2-N + (CH3) 3C1. "Especially advantageously, the products of Eudragit ™ .used in the thermoformable mixture of the invention are the Eudragit ™ RLPO and / or RSPO, which correspond to poly (ethyl acrylate chloride, methyl methacrylate, trimethylaminoethyl methacrylate) 's in the relative proportions of 1: 2: 0.2 and 1: 2: 0.1, respectively According to another advantageous variant of the invention, the thermoformable mixture of the invention may comprise Eudragit ™ of type E. This polymer corresponds to a poly (butyl methacrylate, (2-dimethylaminoethyl) methacrylate) , methyl methacrylate) in the relative proportions of 1: 2: 1 Eudragit ™ type E can be used as the only polymethacrylate polymer in the thermoformable mixture, or it can be used in association with Eudragit ™ RLPO and / or RSPO. Among Eudragit ™ type E products, a special mention can be made of the Eoo Eragragit ™, the particular feature of which is that it is soluble at pH's below 5, allowing rapid release of the active ingredient in the stomach. As a result of this fact, the use of Eudragit ™ of the type E, and more especially of the ElOO type, is especially well suited to obtain solid pharmaceutical compositions of immediate release that are administered by the oral route. According to a third variant of the invention, the thermoformable mixture of the invention may comprise Eudragit ™ of type L100, L100-55 and / or S100. Eudragit ™ L100 corresponds to a poly (methacrylic acid, methyl methacrylate) in the relative proportions of 1: 1. Eudragit ™ L100-55 corresponds to a poly (methacrylic acid, ethyl acrylate) in the relative proportions of 1: 1 Eudragit MR S100 corresponds to a poly (methacrylic acid, methyl methacrylate) in the relative proportions of 1: 2. These types of Eudragit ™ can be used as the sole polymethacrylate polymer in the thermoformable mixture, or they can be used in association with one or more other types of Eudragit ™ mentioned above. These polymethacrylates are soluble at pH 's of more than 5.5, thereby allowing the release of the active ingredient in the intestine and colon. The use of the Eudragit ™ products is especially valuable for obtaining gastro-resistant solid controlled pharmaceutical compositions. The pharmaceutical compositions obtained by means of this within the context of the invention unexpectedly allow the controlled release of the active ingredient (s) to be obtained during a period of from several minutes to more than 20 hours, It is possible that this release is linear depending on the active ingredient incorporated, the manufacture of the matrix and the technique used. The pharmaceutical compositions of the invention are therefore obtained by mixing at least one active ingredient and one or more polymethacrylate polymers, decreasing the viscosity of the mixture under the effect of heat and the shearing forces of an endless screw. Within a cylinder, and then a treatment of the molten mixture by one of the following means: expulsion of the extruder through a calibrated orifice of variable size and shape, the material obtained is subsequently cut according to the final desired shape of the matrix; this constitutes the simple extrusion technique; or the first extruder containing the reduced viscosity mixture described above is associated with a second extruder containing a mixture containing: * either, only one or more polymethacrylate (s) for the control of the release of the active ingredient (s) from the central portion, or one or more polymethacrylate (s) in admixture with one or more active ingredient (s), which may be the same or different than that (or those) content (s) in the central portion, each extruder operating continuously and feeding the same orifice; the hole allows the passage of the mixture coming from the first extruder, ensuring the formation of the inner layer of the final matrix, and also the passage of the mixture coming from the second extruder, ensuring the formation of the outer layer of the final matrix; the extruded material obtained by this is then cut according to the desired final shape, and may optionally undergo molding; the ends of the extruded material can optionally be closed by means of appropriate technology; this constitutes the co-extrusion technique; or injection under pressure, inside a press, in molds having a perfectly defined shape and volume according to the desired geometrical characteristics for the matrix; this constitutes the injection technique; or the press is equipped with a plurality of injection units, which allow injection to one and the same mold, sequentially or simultaneously, of at least two mixtures, which. they can be the same or different; the first injection unit injects the mixture, described in the foregoing, which constitutes the central portion, or heart, of the matrix; the second injection unit injects, at the periphery of the central portion, an outer layer of a mixture comprising: * either only one or more polymethacrylate (s) for the control of the release of the ingredient (s) ( s) active (s), * or one or more polmethacrylate (s) in admixture with one or more active ingredient (s), which may be the same as or different from that (or those) contained in the central portion; This constitutes the technique of co-injection, which at the same time includes the techniques of injection of multiple components and the injection of "sandwich". According to the technique employed, it is therefore possible, within the context of the present invention, to obtain solid controlled release pharmaceutical compositions which are especially administrable by the oral, buccal, sublingual, ocular, rectal, vaginal or parenteral routes, which they are of variable size and geometry, are composed of one layer or multiple layers, and are well suited for the most appropriate release profiles for each therapeutic agent. The pharmaceutical compositions can be used directly, without carrying out another transformation technique apart from packaging. If desired, however, the pharmaceutical compositions can undergo transformation by grinding or granulation for introduction into a gelatin capsule, or by compression, or they can be attached to a coating.

The pharmaceutical compositions of the invention can optionally also comprise pharmacologically acceptable excipients selected, for example, from the group of antioxidants, flavors, colorants, preservatives, sweeteners and anti-adherents. The thermoforming temperature is from 60 ° C to 150 ° C. The temperature is preferably from 80 ° C to 130 ° C. Among the active ingredients incorporated into the composition according to the invention, can be mentioned, without implying any limitation, penicillins, cephalosporins, cyclins, beta-lactamase inhibitors, inosides, quinolones, nitroimidazole compounds, sulfamides or antibacterials, antihistamines, anti-allergics, anesthetics, steroidal or nonsteroidal anti-inflammatory drugs, antalgic agents that have local or systemic action, antispasmodics, agents anti-cancer, diuretics, beta-blockers, antihypertensives, antianginal agents, anti-arrhythmics, vasodilators, bradycardia, calcium inhibitors, sedatives, cardiotonics, antifungals, anti-ulcerative, venotonic, vasculoprotective, anti-ischemic, anti- emetics, anticoagulants, antithrombotics, immunosuppressants, immunomodulators, antivirals, antidiabetes, age Hypolipidemic agents, antiobesity agents, anticonvulsants, hypnotics, antiparkinson agents, antimigraine agents, neuroleptics, anxiolytics, antidepressants, antipsychotics, psychostimulants, memory enhancers, bronchodilators, antitussives, anti-osteoporotics, peptide hormones, steroids, enzymes, enzyme inhibitors, and melatoninergic agonists and antagonists. The following Examples illustrate the invention but do not limit it in any way.

EXAMPLE 1: The compositions of Example 1 were obtained by the extrusion technique. All contained 125 mg of active ingredient, ie benfluorex hydrochloride. The compositions were composed of a mixture comprising 50% active ingredient and 50% polymethacrylate. Example 1 shows the influence of the nature of the polymethacrylates used on the in vitro dissolution kinetics of the active ingredient. In batches 1 to 5, which have a constant weight of polymethacrylates, the amount of Eudragit ™ RLPO relative to that of Eudragit ™ RSPO accordingly varies from 100 to 0%. When the RSPO Eudragit ™ is absent from the mixture, the release of the active ingredient is observed over a period of 16 hours. The addition of a small amount of Eudragit ™ RSPO allows the rate of benfluorex release to be controlled.

Table 1: Variation of the relationship of Eudragit118 RLPO / RSPO of a composition containing 125 mg of benfluorex hydrochloride Kinetics of dissolution i n vi tro are presented in the attached Figure 1.

EXAMPLE 2 -. - ___ The compositions of Example 2 were obtained by the extrusion technique. All contained 3.2 mg of active ingredient, ie rilmenidine dihydrogen phosphate. The compositions were composed of a mixture comprising 10% active ingredient and 90% polymethacrylate. Example 2 confirms the observations obtained in Example 1 related to the influence of the nature of the polymethacrylates used on the in vitro release of the active ingredient. The control of the release of the active ingredient is obtained by varying the amount of Eudragit "* RLPO relative to that of the Eudragit M" R * RSPO Table 2: Variation of the EudragitMR ratio RLPO / RSPO of a composition containing 3.2 mg of rilmenidine dihydrogen phosphate The dissolution kinetics in vi tro are presented in Figure 2 appended.

EXAMPLE 3: The composition of Example 3 was obtained by the extrusion technique. It contained 150 mg of active ingredient, ie fenspiride hydrochloride. The composition was composed of a mixture comprising 30% active ingredient and 70% polymethacrylate, the latter being only Eudragit ™ RLPO. Example 3 shows the weak influence of the pH of the dissolution medium on the release kinetics of the active ingredient, as illustrated in Figure 3 (attached), which shows the dilution profile at pH = 2 and the dissolution profile at pH = 7.4. The in vitro dissolution kinetics are presented in Figure 3 attached, EXAMPLE: The compositions of Example 4 were obtained by the extrusion technique. They contained 150 mg of active ingredient, ie fenspiride hydrochloride. The compositions were composed of a mixture comprising 30% active ingredient and 70% polymethacrylate, the latter being either Eudragit ™ RLPO or Eudragit ™ ElOO. Example 4 shows a much faster release at pH 2 with Eudragit ™ ELOO than with Eudragit ™ RLPO. The in vitro dissolution kinetics are presented in the attached Figure 4.

. EXAMPLE 5: The composition of Example 5 was obtained by the extrusion technique. It contained 135 mg of active ingredient, ie benfluorex hydrochloride. The compositions were composed of a mixture comprising 50% active ingredient and 50% polymethacrylate, the latter was Eudragit RLPO The release of the active ingredient as a function of time is linear for 6 hours, with zero order kinetics. In vitro dissolution kinetics are presented in Figure 5 attached.

EXAMPLE 6: The compositions of Example 6 were obtained by the co-extrusion technique. All contained 135 mg of active ingredient, ie fenspiride hydrochloride. The inner layer was composed of a mixture of 30% fenspiride and 70% Eudragit ™ RLPO. The outer layer was composed of 100% Eudragit ™ - RLPO. The presence of an outer layer of polymethacrylate RLPO allows the release kinetics of the active ingredient of the inner layer to be moderate.

Increasing the thickness of the outer layer from 0.1 mm to 0.4 mm allowed the kinetics of release of the active ingredient to be even more moderate, and obtain a "resting time" or latency time of about 4 hours before the release of the ingredient active. In vitro dissolution kinetics are presented in Figure 6 attached.

EXAMPLE 7: The composition of Example 7 was obtained by the extrusion technique. It contained 59 mg of active ingredient, ie (lR) -l- ( { - [[(2R) -2- (acetylamino) -3-phenylpropanoyl] (cyclopentyl-1) -amino] -acetyl} -hydrochloride. amino) -4-. { [amino (imino) methyl] amino} butyl boronic. The composition was composed of a mixture comprising 59% active ingredient and 41% polymethacrylate, the latter being Eudragit ™ RLPO. The in vitro release of the active ingredient was prolonged for four hours (Figure 7). The results of the plasma concentrations obtained in humans (n = 12) after administration by the oral route of the extruded material containing 59 mg of the active ingredient are presented in Figure 8. Figures 7 and 8 are presented in the annex .

EXAMPLE 8: In the same manner as in Example 1, different compositions composed of a 1/1 mixture of active ingredient / polymethacrylate with various active ingredients were obtained. The compositions contained the following amounts of active ingredient: gliclazide 30 mg piribedil 50 mg - L-tartrate 2 - (. {2-methoxy-2- [3- (tri fluoromet il) -Genyl] ethyl} amino) ethyl-4-2 (2- { [2- (9H-fluoren-9-11) acetyl] amino.} ethyl) benzoate. 200 mg 3a, 10-dihydro-5, 5-dioxo-4H- (S) -pyrrolidino [1, 2-c] - [1, 2, 4] benzothiadiazine 100 mg - N- [2- (5-ethyl-l- benzothien-3-yl) ethyl] acetamide. 100 mg As in Example 1, it is observed with these different compositions that the variation of the amount of Eudragit ™ RSPO relative to that of Eudragit ™ RLPO makes it possible for the release rate of the active ingredient to be varied, and therefore controlled as required.

EXAMPLE 9: In the same manner as in Example 2, different compositions composed of a 1/9 mixture of active ingredient / polymethacrylate with various active ingredients were obtained. The compositions contained the following amounts of active ingredient: indapamide 1.5 mg - tertatolol hydrochloride 5 mg Control of the release of the active ingredient was obtained by varying the amount of Eudragit ™ RLPO relative to that of Eudragit ™ RSPO.

EXAMPLE 10: The compositions of Example 10 were obtained by the extrusion technique according to the protocol described in Example 2, but in this case they contained 25 mg of N- [2- (7-methoxy-1-naphthyl) ethyl] acetamide , and they were composed of a mixture comprising 30% active ingredient and 70% polymethacrylate.

EXAMPLE 11 The compositions of Example 11 were obtained as those of Example 6, but contained 100 mg of N- [2- (5-ethyl-1-benzothien-3-yl) ethyl] acetamide instead of fenspiride.

Claims (27)

1. CLAIMS 1. Controlled release solid pharmaceutical composition, characterized in that it comprises a thermoformable mixture of at least one active ingredient and one or more polymers selected from the group of polymethacrylates, the release of the active ingredient (s) is controlled only by the nature of the polymethacrylate (s) used, by the amount thereof relative to the active ingredient (s), and by the technique employed in the manufacture of the composition.
2. 2. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the polymethacrylate (s) used in the thermoformable mixture belong to the family of Eudragit ™ RL and / or RS products.
3. 3. Controlled release solid pharmaceutical composition according to either claim 1 or claim 2, characterized in that the polymethacrylate (s) used in the thermoformable mixture is / are Eudragit ™ RLPO and / or Eudragit ™ RSPO
4. 4. Controlled release solid pharmaceutical composition according to any of claims 1 to 3, characterized in that the thermoformable mixture comprises Eudragit ™ type E, alone or in association with one or more of the Eudragit ™ products mentioned in the foregoing.
5. 5. Controlled release solid pharmaceutical composition according to any of claims 1 to 4, characterized in that the thermoformable mixture comprises Eudragit ™ of type L100, L100-55 and / or SlOO, alone or in association with one or more of the aforementioned Eudragit ™ products. in the above.
6. 6. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the composition is administrable by one of the selected routes of the oral, buccal, sublingual, ocular, vaginal, rectal and parenteral routes.
7. 7. Controlled release solid pharmaceutical composition according to any of claims 1 to 6, characterized in that the composition is administrable by the oral route.
8. 8. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the thermoforming temperature of the mixture is from 60 ° C to 150 ° C.
9. 9. Controlled release solid pharmaceutical composition in accordance with either claim 1 or claim 8, characterized in that the thermoforming temperature of the mixture is from 80 ° C to 130 ° C.
10. 10. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the mixture is thermoformed according to the extrusion technique.
11. 11. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the mixture is thermoformed according to the injection technique.
12. 12. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the mixture is thermoformed according to the co-extrusion technique, the internal layer of the composition in this case is composed of the mixture, and the outer layer of the The composition is composed of either one or more polymethacrylate (s), or one or more polymethacrylate (s) in admixture with one or more active ingredient (s), which may be the same or different than that / those content (s) in the inner layer.
13. 13. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the mixture is thermoformed according to the co-injection technique, the central portion of the composition in this case is composed of the mixture, and the outer layer of the The composition is composed of either one or more polymethacrylate (s), or one or more polymethacrylate (s) in admixture with one or more active ingredient (s), which may be the same or different than that / those content (s) in the central portion.
14. 14. Controlled release solid pharmaceutical composition according to claim 1, characterized in that it optionally contains one or more pharmacologically acceptable excipients selected from anti-oxidants, flavors, colorants, preservatives, sweeteners and anti-adherents.
15. 15. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient (s) are selected from anti-infective agents such as penicillins, cephalosporins, cyclins, beta-lactamase inhibitors, aminosides, quinolones, nitrqimidazole compounds, sulfonamides or antibacterials, antihistamines, anti-allergic, anesthetics, steroidal or nonsteroidal anti-inflammatories, antalgic agents that have local or systemic action, antispasmodics, anti-cancer agents, diuretics, beta-blockers, antihypertensives, agents anti-angina, ant i-arrhythmics, vasodilators, bradycardia, calcium inhibitors, sedatives, cardiotonics, antifungals, anti-ulcerative, venotonic, vasculoprotective, anti-ischemic, antiemetic, anticoagulant, antithrombotic, immunosuppressive, immunomodulatory, antiviral, antidiabetes, hypolipidemic agents, antiobesity agents , anticonvulsants, hypnotics, antiparkinson agents, antimigraine agents, neuroleptics, anxiolytics, antidepressants, antipsychotics, psychostimulants, memory enhancers, bronchodilators, antitussives, ant i-osteoporotics, peptide hormones, steroids, enzymes, enzyme inhibitors, and agonists and Melatoninergic antagonists.
16. 16. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient is benfluorex hydrochloride.
17. 17. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient is rilmenidine dihydrogen phosphate.
18. 18. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient is fenspiride hydrochloride.
19. 19. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient is (IR) -1- ( { - [[(2R) -2- (acetylamino) -3-phenylpropanoyl] hydrochloride] ( cyclopentyl) -amino] -acetyl.} amino) -4-. { [amino (imino) methyl] amino} butyl boronic.
20. 20. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient is glycazide.
21. 21. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient is pyribedil.
22. 22. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient is 2- (. {2-methoxy-2- [3- (trifluoromethyl) phenyl] ethyl} amino) ethyl-tartrate -4-2- (2- { [2- (9H-Fluoren-9-yl) acetyl] amino.} Ethyl) benzoate.
23. 23. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient is 3a, 10-dihydro-5, 5-dioxo-4H- (S) -pyrrolidino- [1,2-c] [1, 2 , 4] benzothiadiazine.
24. 24. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient is N- [2- (5-ethyl-l-benzothien-3-yl) ethyl] acetamide.
25. 25. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient is indapamide.
26. 26. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient is tertatsol.
27. 27. Controlled release solid pharmaceutical composition according to claim 1, characterized in that the active ingredient is N- [2- (7-methoxy-1-naphthyl) ethyl] acetamide.